Daniel Berney
@daniel_berney
Followers
4K
Following
6K
Media
625
Statuses
5K
Uro/endo Histopathologist at @bartshistopath. Prof GU Path: @histo_journal. Intermittently here: https://t.co/RI2UDSGTVj Singer and Gay Dad 🏳️🌈🐶
QMUL, Bartshealth
Joined January 2018
Before leaving this benighted forum, just to say to all my great fellow Twitter friends I’m turning 60 soon and celebrating with my first 10k run for Bart’s charity on Sunday! Click the link to find out why!
2025vitalitylondon10000.enthuse.com
To commemorate my 60th Birthday and the fact the whole of my working life has been at Barts or the London, I am running my first 10K. Not much for some...but a lot for a Berney! I started in pathology
0
0
4
Thanks: I’m done here though. Downloading all my info and then deleting account.
0
0
0
No matter how hard I try, I still get vile horrible posts appearing on my X feed. Today, homophobic rubbish about what a bad parent I am because I am gay. Although I love #pathtwitter and being part of the path community, I‘ve had enough. Follow me on linked in or blue sky.
2
0
6
Delighted to spend the day with the lovely @Tretiakova_Mar, and show her our hospitals and a bit of London! Think @NHSBartsHealth was a bit of a surprise! Love the look on doctor’s faces when I say ‘founded 1123’!
0
0
17
Thought it was appropriate to remind everyone over the pond ( with love) what a case with REAL mitochondrial ‘challenges’ actually looks like.
0
0
7
tracking down clinician to get needed clinical history on a tough🔬case
5
12
88
#GUpath testicular germ cell tumor: mixed seminoma+yolk sac tumor in the center? nope! all seminoma, with admixed rete hyperplasia (would be PAX8+) containing globules 🚨diagnostic pitfall! ✔️our recent study led by @SPotterveld PMID: 39437183
1
32
78
Correct! Extremely bland histology but this is a muscle invasive VERY bland microcystic nested UC!
0
0
6
Example of a ‘shoulder’ lesion in a high grade non invasive UC. Don’t overcall this as CIS. The edge of the papillary lesion creeps into flat urothelium. #bladderpath #gupath. @MichelleDunno17 speaks well on this subject!
3
25
95
Today we had our annual germ cell supraregional meeting. I spoke about sex cord stromal tumours, but Miss Li our urologist/andrologist put up a slide I can’t easily forget….
1
1
7
Ongoing problems in medicine, part 376 : yes you have shown me the evidence and I agree that it is compelling that screening doesn’t work, nevertheless the screening that I do is different and has saved lives /…
2
6
38
It was great to be part of the GU session at Ghent Pathology. Great opportunity to catch up with colleagues and dear friends @daniel_berney @BritishDivIAP @GU_Path_Society @IntSocUropath
2
3
42
Prof Andres Acosta introducing molecular testing in GU pathology @pathsoc Ghent 2025 @Andres_M_Acosta
0
2
7
CONGRATULATIONS to winner of the Cotton prize for best paper in 2024: Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii - Neyrand - 2024 -#gynpath #endopath
onlinelibrary.wiley.com
Benign struma ovarii shows significantly fewer molecular alterations than malignant struma. BRAF and TERT promoter mutations are seen only in malignant tumours. BRAF p.G469A mutation is frequent in...
0
5
18
CONGRATULATIONS to winner of the MacSween prize for best paper by a resident 2024. Prognostic performance of FIGO 2023 endometrial Ca staging: a comparison to FIGO 2009 staging.. #gynpath - Libert - 2024 - Histopathology - Wiley Online Library
onlinelibrary.wiley.com
2023 FIGO endometrial cancer staging significantly updates the 2009 criteria. Evaluating 404 patients, this study shows improved prognostication using molecular data, especially with POLE mutations...
1
8
21
The EIC is at the @wiley desk at the @BritishDivIAP @pathsoc Ghent summer meeting if anyone wants advice or help on submissions!
0
4
11
Delighted to announce our new Impact Factor of 4.1. IF, however, is only one measure of a journal’s worth. We publish to be of interest and use to general histopathologists and to ease as far as we are able the publication process with fast decisions and constructive reviews.
0
5
21